CANSINOBIO (06185) experienced a sharp rally of over 8% during the morning trading session. As of press time, the stock was up 8.05% to HK$52.75, with trading volume reaching HK$95.46 million.

On the news front, CANSINOBIO released its interim results showing revenue of approximately 374 million yuan, representing a year-on-year increase of 31.1%. The company's attributable net loss for the period was 13.485 million yuan, narrowing significantly by 94.02% compared to the same period last year.

During the reporting period, the company continued to advance the commercialization of its meningococcal conjugate vaccine. As of the report date, Menhein has been successfully commercialized in China's mid-to-high-end vaccine market, with its market penetration rate continuing to improve. The company's meningococcal conjugate vaccine generated sales revenue of approximately 364 million yuan, an increase of 38.4% compared to the same period last year, contributing to the company's stable revenue growth.